



# The power of mRNA: transforming healthcare beyond COVID-19

**Jolanda Crombach, Managing Director at Moderna, the Netherlands**




Meet the Dutch management team



Jolanda Crombach  
General Manager-Director

Vincent Lempers  
Medical Director

Joep Blisselink  
Pharmacovigilance Country Head - Benelux



Marly van Bragt  
Marketing Director

Tjalke Westra  
Market Access Director


Our mission

**Deliver** the greatest possible impact  
to **people** through mRNA **medicines**

[Video link](#)



# Our platform enabled us to develop and deliver an authorized vaccine against COVID-19 in record time in 2020



# Our Big Moments – Global

**2010**

## Moderna Incorporates

Moderna's name combines the words "modified" and "RNA", which happens to contain the word "modern."

**2014**

## Expansion

New headquarters and labs open in Cambridge, Massachusetts.

**2016**

## New lease signed

Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA

**2018**

## New facility opens

Moderna opens its state-of-the-art clinical development site in Norwood, MA.

**2020**

## CDC recommendation

The U.S. Centers for Disease Control and Prevention votes to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older in the U.S.

**2024**

## Moderna receives approval for its RSV vaccine

Moderna's second product, mRESVIA, an RSV vaccine, is approved in the U.S., Europe, Canada & Qatar

**2011**

## Operations started

Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.

**2015**

## First human dose of flu vaccine

Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.

**2017**

## First human dose of multivalent vaccine

Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus.

**2019**

## First antibody encoded by mRNA


Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial.

**2022**

## Moderna receives full approval for COVID-19 vaccine by U.S. FDA

The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.

# Moderna's impact




~**6,000** employees  
in **21** locations  
worldwide (June 2023)



More than a **billion**  
doses delivered  
around the world

moderna


# Moderna was founded and built to use nature's information molecule, mRNA, to treat and prevent disease



**mRNA-based medicine could move at the pace of information by leveraging a common platform**


# Investing in a platform to deliver on the promise of mRNA

10+ years of investment creating a singular platform






# The promise of mRNA




- 1 Large opportunity to address unmet need
- 2 Higher efficiency in R&D
- 3 Rapid and agile development
- 4 Greater capital efficiency

# Moderna's development portfolio



# AI is not new to Moderna




# Moderna's global health strategy is a recognition that mRNA-based vaccines could continue to have a significant impact on public health



## Regional Manufacturing

**Operate mRNA manufacturing facilities around the world to be ready to respond to any regional outbreak**



## Priority Pathogens

**Commitment to advance vaccines targeting at least 15 priority pathogens into clinical studies by 2025**



## mRNA Access™

**Collaborative program enabling researchers around the world to utilize Moderna's mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases**



[Video link](#)

# Key ESG highlights (from ESG Report 2023)

## Medicines for patients

**100 million**

people impacted in 2023

**+40**

development programs

**9**

programs in late-stage development

**\$4.8 billion**

in R&D investment

## Global public health

**12**

priority pathogens in research and development

**18**

institutions participating in mRNA Access

## Employees

**49%**

women in workforce

**39%**

women executives

**9**

Employee Resource Groups

## Equal pay for equal work study



## Environment

Committed to net-zero carbon emissions in Scope 3 by 2045

Published Scope 3 emissions, water usage, and water management usage

Incorporated sustainability into the design and construction of new manufacturing plants

Performed climate risk and scenario analysis project

Complete energy, water and waste assessments at our manufacturing facility in Norwood

## Community

**169%**

increase in tracked volunteer hours from 2022

**70%**

employee participating rate in volunteering and/or giving

**2,390**

Nonprofits supported globally

**\$7.2 million**

in grants by the Moderna Charitable Foundation in 2023

**\$1.3 million**

in donations from employee matching program in 2023

**\$1.4 million**

in grants by the Moderna Charitable Foundation focused on humanitarian disaster relief in 2023

## Governance & ethics

**97%**

of employees trained in Reimagined Code of Ethics and Business Conduct

Launched double-materiality assessment

## Awards

### BioSpace's Best Places to Work


Ranked number 1 in large employer category on 2024list

### Science Careers' Top Employers

Ranked for tenth consecutive year

# Incorporating new vaccines into the Dutch healthcare system

## Key actions for successful implementation



moderna®

